Tiger Brokers

Rafael Holdings Q2 FY2026 R&D expenses more than tripled to USD 4.53 million as net loss attributable to shareholders widened 38.3% to USD 6.42 million

Reuters
Mar 17
Rafael Holdings <a href="https://laohu8.com/S/QTWO">Q2</a> FY2026 R&D expenses more than tripled to USD 4.53 million as net loss attributable to shareholders widened 38.3% to USD 6.42 million

Rafael Holdings published a quarterly earnings release reporting second-quarter fiscal 2026 results. Net loss attributable to shareholders widened 38.3% to USD 6.4 million, or USD 0.13 per share. Research and development expenses rose more than tripled to USD 4.5 million, reflecting the inclusion of Cyclo Therapeutics spending following the March 2025 acquisition. Cash and cash equivalents were USD 37.78 million as of Jan. 31, 2026. Howard Jonas said the Phase 3 TransportNPC study of Trappsol Cyclo in Niemann-Pick Disease Type C1 will continue after a Data Monitoring Committee review at 48 weeks, and Joshua Fine said the company expects to report preliminary topline results in the third quarter of the calendar year.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rafael Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603161601PRIMZONEFULLFEED9672964) on March 16, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10